Allianz SE purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 103,250 shares of the company's stock, valued at approximately $444,000. Allianz SE owned about 0.56% of Genenta Science at the end of the most recent reporting period.
Genenta Science Stock Down 7.0 %
Shares of Genenta Science stock traded down $0.27 during trading on Friday, hitting $3.61. 2,332 shares of the stock were exchanged, compared to its average volume of 14,820. Genenta Science S.p.A. has a 1-year low of $2.20 and a 1-year high of $7.28. The company has a fifty day moving average price of $3.93 and a 200-day moving average price of $4.52.
About Genenta Science
(
Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Recommended Stories
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
